Overlapping synthetic peptides as vaccines
Jiang et al – 2006 (view as PDF)...
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
- Seeking Series B investment for next phase of clinical trials
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
News & Articles
Expression and clinical significance of survivin in ovarian cancer: A meta-analysis
He et al – 2018 (view as PDF)...
Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
Guidance for Industry, Clinical Considerations for Therapeutic Cancer Vaccines (view as PDF)...
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Fenstermaker et al – 2016 (view as PDF)...
Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins
Cai et al -2017 (view as PDF)...
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
Berinstein et al – 2015 (view as PDF)...
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, Adida and Altieri -1997 (view as PDF)...
Cancer vaccine firm Oxford Vacmedix appoints leading global CRO to run Phase 1 trial of OVM-200
Oxford Vacmedix appoints a Global Contract Research Organisation (CRO) to run a Phase 1 trial of immunotherapy cancer vaccine OVM-200 in the UK. Oxford, UK – 24th January 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that a leading global CRO has been appointed to run the Phase 1 trial of lead immunotherapy cancer vaccine, OVM-200. The trial will be the first time that OVM’s novel proprietary Recombinant O...
Contact Us
If you have any questions or want to get in touch, please contact our team.
(c) 2025 Oxford Vacmedix UK Limited | Company Registration: 07994205
English